Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNXNASDAQ:LIVNNASDAQ:NVCRNYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$19.09-2.1%$13.92$8.89▼$24.50$827.67MN/A499,635 shs454,762 shsLIVNLivaNova$45.76-1.9%$40.58$32.48▼$57.35$2.50B0.9644,196 shs417,134 shsNVCRNovoCure$17.55-3.6%$17.46$14.17▼$34.13$1.96B0.741.18 million shs1.35 million shsWRBYWarby Parker$22.04-1.9%$17.91$12.46▼$28.68$2.30B2.11.95 million shs2.24 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics-2.05%+0.05%+48.68%+30.13%+1,908,999,900.00%LIVNLivaNova-1.87%-0.41%+5.07%+16.62%-13.35%NVCRNovoCure-3.57%+3.24%+2.63%-9.95%-17.41%WRBYWarby Parker-1.56%+2.01%+26.45%+7.55%+33.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBNXBeta BionicsN/AN/AN/AN/AN/AN/AN/AN/ALIVNLivaNova3.4659 of 5 stars3.54.00.00.03.21.71.3NVCRNovoCure3.8964 of 5 stars3.34.00.04.51.41.70.0WRBYWarby Parker2.052 of 5 stars2.32.00.00.03.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.73Moderate Buy$23.1321.14% UpsideLIVNLivaNova 3.00Buy$59.2929.56% UpsideNVCRNovoCure 2.67Moderate Buy$32.8387.08% UpsideWRBYWarby Parker 2.61Moderate Buy$22.883.78% UpsideCurrent Analyst Ratings BreakdownLatest BBNX, LIVN, WRBY, and NVCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025BBNXBeta BionicsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$30.005/30/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$16.005/30/2025BBNXBeta BionicsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.005/29/2025WRBYWarby ParkerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $25.005/22/2025WRBYWarby ParkerRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.005/21/2025WRBYWarby ParkerCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$17.00 ➝ $22.005/21/2025WRBYWarby ParkerStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$18.00 ➝ $21.005/21/2025WRBYWarby ParkerTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $24.005/20/2025LIVNLivaNovaWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$60.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$69.83M11.85N/AN/AN/A∞LIVNLivaNova$1.28B1.96$4.10 per share11.15$23.72 per share1.93NVCRNovoCure$621.71M3.15N/AN/A$3.39 per share5.18WRBYWarby Parker$795.09M2.90N/AN/A$3.08 per share7.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta BionicsN/AN/A0.00∞N/AN/AN/AN/AN/ALIVNLivaNova$17.55M-$4.09108.9514.57N/A1.91%13.81%7.07%7/30/2025 (Estimated)NVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)WRBYWarby Parker-$63.20M-$0.12N/A220.41N/A-4.39%-8.26%-4.37%8/6/2025 (Estimated)Latest BBNX, LIVN, WRBY, and NVCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025BBNXBeta Bionics-$0.51-$0.52-$0.01-$0.93N/AN/A4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million3/25/2025Q4 2024BBNXBeta Bionics-$0.42-$1.82-$1.40-$2.72$20.01 million$20.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/ALIVNLivaNovaN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/AN/AN/ALIVNLivaNova0.463.372.87NVCRNovoCure0.271.491.44WRBYWarby ParkerN/A2.472.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/ALIVNLivaNova97.64%NVCRNovoCure84.61%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/ALIVNLivaNova0.29%NVCRNovoCure5.52%WRBYWarby Parker18.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.36 millionN/AN/ALIVNLivaNova2,90054.53 million54.15 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableWRBYWarby Parker3,030104.50 million74.67 millionOptionableBBNX, LIVN, WRBY, and NVCR HeadlinesRecent News About These CompaniesWarby Parker Inc. (NYSE:WRBY) Receives $22.88 Average Price Target from BrokeragesJune 14 at 2:05 AM | americanbankingnews.comTech Giants Partner With Retailers As Smart Glasses Battle Heats UpJune 12 at 2:14 PM | forbes.comWarby Parker eyes space at trendy Raleigh shopping centerJune 11 at 5:32 PM | bizjournals.comWarby Parker Inc. (NYSE:WRBY) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 11 at 2:44 AM | marketbeat.comWRBY Q1 Earnings Call: Management Details Tariff Mitigation, Store Expansion, and Pricing ActionsJune 10, 2025 | msn.comNBC Securities Inc. Buys 11,574 Shares of Warby Parker Inc. (NYSE:WRBY)June 9, 2025 | marketbeat.comAmeriprise Financial Inc. Acquires New Shares in Warby Parker Inc. (NYSE:WRBY)June 6, 2025 | marketbeat.comWarby Parker Co-CEO: Google AI Glasses Coming After 2025June 4, 2025 | pymnts.comWarby Parker (NYSE:WRBY) Shares Down 3.3% - What's Next?June 4, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.29 Million Holdings in Warby Parker Inc. (NYSE:WRBY)June 3, 2025 | marketbeat.comWarby Parker Announces Participation in the Baird Global Consumer, Technology & Services ConferenceJune 2, 2025 | finance.yahoo.comJune 2, 2025 | gurufocus.comWarby Parker (NYSE:WRBY) Trading Up 3% - Still a Buy?May 31, 2025 | marketbeat.comInsider Selling: Warby Parker Inc. (NYSE:WRBY) Director Sells 33,073 Shares of StockMay 29, 2025 | marketbeat.comTwo Sigma Advisers LP Increases Stake in Warby Parker Inc. (NYSE:WRBY)May 29, 2025 | marketbeat.comGoogle Is Back to Smart Glasses: This Time It Might WorkMay 28, 2025 | techopedia.comYoungme E. Moon Sells 33,073 Shares of Warby Parker Inc. (NYSE:WRBY) StockMay 28, 2025 | insidertrades.comWarby Parker Inc. (NYSE:WRBY) Shares Acquired by Two Sigma Investments LPMay 28, 2025 | marketbeat.comLoop Capital Maintains Buy Rating on Warby Parker (WRBY) StockMay 27, 2025 | insidermonkey.comWoodline Partners LP Sells 85,914 Shares of Warby Parker Inc. (NYSE:WRBY)May 27, 2025 | marketbeat.comMan Group plc Sells 18,862 Shares of Warby Parker Inc. (NYSE:WRBY)May 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBNX, LIVN, WRBY, and NVCR Company DescriptionsBeta Bionics NASDAQ:BBNX$19.09 -0.40 (-2.05%) As of 06/13/2025 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.LivaNova NASDAQ:LIVN$45.76 -0.87 (-1.87%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$45.74 -0.02 (-0.04%) As of 06/13/2025 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.NovoCure NASDAQ:NVCR$17.55 -0.65 (-3.57%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$17.57 +0.02 (+0.11%) As of 06/13/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Warby Parker NYSE:WRBY$22.04 -0.42 (-1.87%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$22.16 +0.11 (+0.52%) As of 06/13/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
